Alliance Pharma (LON:APH) Price Target Cut to GBX 60

Alliance Pharma (LON:APHFree Report) had its price objective lowered by Royal Bank of Canada from GBX 65 ($0.83) to GBX 60 ($0.76) in a research report sent to investors on Wednesday morning, MarketBeat.com reports. The brokerage currently has an outperform rating on the stock.

Alliance Pharma Stock Performance

LON:APH opened at GBX 39.15 ($0.50) on Wednesday. The company has a market capitalization of £211.56 million, a PE ratio of -3,915.00, a P/E/G ratio of 1.04 and a beta of 0.57. The company has a 50 day simple moving average of GBX 38.71 and a two-hundred day simple moving average of GBX 42.14. The company has a debt-to-equity ratio of 45.00, a quick ratio of 1.42 and a current ratio of 1.93. Alliance Pharma has a fifty-two week low of GBX 33.70 ($0.43) and a fifty-two week high of GBX 73.04 ($0.93).

About Alliance Pharma

(Get Free Report)

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics.

See Also

Receive News & Ratings for Alliance Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma and related companies with MarketBeat.com's FREE daily email newsletter.